"covid-19" development of human immune globulin (covid-HIG) manufactured from human plasma with antibodies to sars-COV-2 for prevention of coronavirus disease (covid-19)
Ended Other Transaction Agreement Awarded Last action
- Contract number
- W911QY2090013
- Awardee
-
Emergent Biosolutions Canada Inc. UEI XM23STFMVML6 Part of Emergent Biosolutions Inc.
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $34,568,578
Award facts
- Contract value 100% obligated
- $34,568,578.43 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$1,384,872 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | -$2,791,670 | |
| Supplemental Agreement for work within scope | $4,100,000 | |
| Original award | $34,645,120 |
About this award
The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded an Other Transaction Agreement to Emergent Biosolutions Canada Inc. valued at $34.6 million to support the development of human immune globulin (COVID-HIG) manufactured from human plasma with antibodies to SARS-CoV-2. The contract aims to prevent coronavirus disease (COVID-19) through October 2022. Performance will take place at Emergent Biosolutions Canada Inc.'s facility in Ottawa, Ontario. The award was issued under an unspecified vehicle and does not contain any set aside designations. As the Joint PEO Chemical and Biological Defense works to develop medical countermeasures against chemical and biological threats, this contract leverages the contractor's expertise and facilities to support the U.S. government's COVID-19 response efforts through a critical plasma-derived therapy.
Quick answers
Who was awarded contract W911QY2090013?
W911QY2090013 was awarded to Emergent Biosolutions Canada Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on June 24, 2020.
How much is contract W911QY2090013 worth?
The government has obligated $34,568,578 on W911QY2090013.
Which agency awarded contract W911QY2090013?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY2090013, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY2090013 competed?
The extent of competition for W911QY2090013 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award